In this episode of WhatKeepsYouAwake.TV, host David Hooser sits down with Jeff Glazier, co-founder and CEO of General Oncology, a biopharmaceutical company advancing a promising treatment for stage 4 pancreatic cancer. What began as a deeply personal mission—helping a family member survive a diagnosis with a 0% survival rate—has grown into a decade-long journey through clinical trials, scientific risk, and relentless problem-solving.
Jeff shares what truly keeps him awake at night: navigating the countless variables that can derail early-stage biotech, building the right team, and pushing forward when the stakes are measured in human lives.
🎯 Inside This Episode:
• The origin story: how a family cancer diagnosis sparked the creation of General Oncology
• Breakthrough science: developing a low-toxicity treatment for stage 4 pancreatic cancer
• Clinical progress: nearing the end of a Phase 1 trial at Memorial Sloan Kettering
• Quality of life focus: why fewer treatments and fewer side effects matter to patients
• Leadership under pressure: surviving a decade of setbacks, surprises, and high-stakes decisions
📌 Work With / Connect:
• Learn more about General Oncology and its clinical research: generaloncology.com
• Hospitals, research partners, and organizations can connect through the website
🔔 Subscribe to WhatKeepsYouAwake.TV for real conversations with leaders tackling big problems and building mission-driven companies.
📣 Drop a comment: What challenge would be worth losing sleep over if it meant helping others?
🔑 Hashtags:
#JeffGlazier #GeneralOncology #PancreaticCancer #Biotech #ClinicalTrials #CancerResearch #HealthcareInnovation #Leadership #StartupJourney #WhatKeepsYouAwakeTV
